MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on July 2, 2004; DOI: 10.1124/mol.104.000752


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.104.000752v1
66/4/970    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cheng, P.
Right arrow Articles by Nichols, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cheng, P.
Right arrow Articles by Nichols, M.


Received for publication March 26, 2004.
Revised July 1, 2004.
Accepted for publication July 2, 2004.

Inhibition of ER alpha-mediated transcription by antiestrogenic 1,1-dichloro-2,2,3-triarylcyclopropanes

Peng Cheng 1, Beatriz Kanterewicz 1, Pamela A. Hershberger 1, Kenneth S. McCarty, Jr. 1, Billy W. Day 2, Mark Nichols 3*

1 University of Pittsburgh Cancer Institute 2 University of Pittsburgh, School of Pharmacy 3 Hillman Cancer Center, UPCI

* Address correspondence to: E-mail: mnichols{at}pitt.edu

Abstract

A novel class of pure antiestrogens, 1,1-dichloro-2,2,3-triarylcyclopropanes (DTACs), lack estrogenic activity in a mouse uterotrophic assay and inhibit the growth of estrogen-sensitive MCF-7 breast cancer cells (Hossain et al., 1994). Here, reporter assays were used to evaluate the effects of the DTACs on estrogen receptor (ER{alpha})-mediated transcription from either classical estrogen-response elements (EREs) or non-classical AP-1 elements. Among the DTACs tested, only the compounds with smaller aromatic substituents, BDRM72 and BDRM81, displayed weak agonist activity on EREs. Their activity was less than that observed for the ER partial agonist, 4-hydroxytamoxifen (ZOHT). In competition experiments, the DTACs blocked estradiol-stimulated transcription from an ERE in a dose-dependent manner and was a more effective inhibitor than ZOHT. Each of the DTACs was significantly less active than ZOHT or the pure antiestrogen ICI 182,780 in stimulating transcription from non-classical AP-1 elements in the presence of ER{alpha}. DTACs did not modulate either basal or TPA-stimulated transcription from an AP-1 element in the absence of ER{alpha}, indicating that they are not nonspecific inhibitors of transcription and that ER{alpha} is the drug target. GST pull-down assays were used to examine whether DTACs alter the interaction between ER{alpha} and the p160 coactivator, GRIP1. BDRM35, which has the same dimethylaminomethoxy and phenolic moieties as ZOHT, reduced binding by more than 50%. Thus, disruption of p160 coactivator recruitment by ER{alpha} may represent one mechanism by which DTACs function as antiestrogens. BDRM35 also suppresses E2 induction of endogenous target genes c-myc and cyclin D1 in MCF-7 breast cancer cells.


Key words: Sex hormones, Transcriptional coactivators, Regulation of gene expression, Transcription targets, Endocrine cells





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics